April 1, 2021

# Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan

**ENGLEWOOD, CO / ACCESSWIRE / April 1, 2021** /Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. 1720358 for Viveve's dual-energy technology device. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's key markets.

"We are pleased with the issuance of the Taiwanese patent for our dual-energy technology. Taiwan is a key international market for Viveve and plays an important role in influencing women's medical and health trends throughout Asia," said Scott Durbin, Viveve's chief executive officer. "The addition of this newest patent strengthens our intellectual property portfolio, which was recently expanded by a patent issued in South Korea and a U.S. stress urinary incontinence (SUI) patent issued in the fall of 2020. Bolstered by a robust and growing intellectual property estate, we continue to advance our global clinical development and commercialization strategy."

In Taiwan, the Viveve® System is indicated for use in general surgical procedures for anticoagulation and hemostasis. Dynamic Medical Technologies, Inc. remains Viveve's exclusive distribution partner in the country.

**About Viveve**

Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve® System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in more than 50 countries.

Viveve continues to advance its clinical development program in SUI. Recently reported FDA approved changes to the U.S. pivotal PURSUIT trial protocol are intended to strengthen the overall study and its potential to achieve its primary efficacy endpoint. Study changes including an increase in the trial's size and more strict patient selection criteria were a result of guidance from Viveve's Clinical Advisory Board upon review of positive results from the Company's SUI feasibility and preclinical studies. Viveve received FDA approval of its IDE application to conduct the multicenter, randomized, double-blinded, sham-controlled PURSUIT trial for improvement of SUI in women in July 2020 and FDA approval of its requested amendments to the IDE protocol as reported on December 10, 2020. Initiation of the trial was reported on January 21, 2021 and subject enrollment is underway. If positive,

results from the PURSUIT trial may support a new SUI indication in the U.S.

For more information visit Viveve's website at[www.viveve.com](http://www.viveve.com).

**Safe Harbor Statement**

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the impact of the novel coronavirus termed COVID-19 on our clinical development and regulatory review and clearances and on the manufacturing, placements and patient utilization of our Viveve Systems, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

*Viveve is a registered trademark of Viveve, Inc.*

**Investor Relations Contact:**
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

**Media Contact:**
Bill Berry
Berry & Company Public Relations
(212) 253-8881
bberry@berrypr.com

**SOURCE:** Viveve Medical, Inc.

View source version on accesswire.com:
https://www.accesswire.com/638529/Viveve-Announces-Expansion-of-IP-Portfolio-with-Patent-Issuance-in-Taiwan